Zileuton

Research use only, not for human use.

Zileuton (A-64077) is a selective and potent 5-LO inhibitor, and thus inhibits leukotrienes (LTB4, LTC4, LTD4, and LTE4) formation.

Zileuton (A-64077) is a selective and potent 5-LO inhibitor, and thus inhibits leukotrienes (LTB4, LTC4, LTD4, and LTE4) formation.(In Vitro):In anti-CD3-treated cells, IL-2 decreases in zileuton-treated and untreated cells with increasing incubation time. Zileuton likely reduces IL-2 levels by inhibiting 5-lipoxygenase, hence leukotriene B4 production, an IL-2 inducer.(In Vivo):In zileuton (5 mg/kg, p.o.) treated I/R rat, the effect of zileuton to decrease NF-κB expression does not change significantly in the presence of COX inhibitors, and the group reveals significantly lower level of NF-κB staining. Zileuton (5 mg/kg, p.o.) treatment given to I/R rats decreases apoptotic index significantly. Zileuton has no significant effect on increased serum TNF-α levels in I/R group. Zileuton (1,200 mg/kg) inhibits the polyp formation in APCΔ468 colon and small intestine. Zileuton treatment inhibits the proliferation rates of non epithelial cells in polyps, and increases the apoptosis rates in polyps in rat. There is significant increase in the number of apoptotic cells in the Zileuton-treated cells both in small intestine and in the colon. The reduced proliferation rate may significantly contribute to the reduction of polyposis in both the small intestine and colon of Zileuton-fed APCΔ468 mice.

In anti-CD3-treated cells, IL-2 decreases in zileuton-treated and untreated cells with increasing incubation time. Zileuton likely reduces IL-2 levels by inhibiting 5-lipoxygenase, hence leukotriene B4 production, an IL-2 inducer.

In zileuton (5 mg/kg, p.o.) treated I/R rat, the effect of zileuton to decrease NF-κB expression does not change significantly in the presence of COX inhibitors, and the group reveals significantly lower level of NF-κB staining. Zileuton (5 mg/kg, p.o.) treatment given to I/R rats decreases apoptotic index significantly. Zileuton has no significant effect on increased serum TNF-α levels in I/R group. Zileuton (1,200 mg/kg) inhibits the polyp formation in APCΔ468 colon and small intestine. Zileuton treatment inhibits the proliferation rates of non epithelial cells in polyps, and increases the apoptosis rates in polyps in rat. There is significant increase in the number of apoptotic cells in the Zileuton-treated cells both in small intestine and in the colon. The reduced proliferation rate may significantly contribute to the reduction of polyposis in both the small intestine and colon of Zileuton-fed APCΔ468 mice.

A 64077

Chromatin/Epigenetic

COX

COX-1| 5-Lipoxygenase

Neurological Disease

——

111406-87-2

236.29

C11H12N2O2S

>98% (HPLC)

Ethanol: 47 mg/mL (198.9 mM); DMSO: 47 mg/mL (198.9 mM)

O=C(N)N(C(C1=CC2=CC=CC=C2S1)C)O

1-(1-(benzo[b]thiophen-2-yl)ethyl)-1-hydroxyurea

(-20℃)

With Ice Pack

≥ 2 years